<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20190416043290N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-12-17</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of two methods of respiratory support in neonates</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the consequences of using two methods of "continuous positive airway pressure" and "high frequency oscillation" in the treatment of respiratory distress in premature neonates</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-12-05</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>78</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/52187</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Samples are divided into 2 groups by Blocked Randomization method; Thus, the blocks will be 4 and, considering that the sample size is generally 78 people, 20 blocks of 4 will be considered.</study_design>
      <phase>N/A</phase>
      <hc_freetext>respiratory distress of neonates.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1: Infants with a gestational age of 28-34 weeks, weighing less than 2000 grams and hospitalized in the neonatal intensive care unit with a diagnosis of respiratory distress during the first 24 hours of birth, entered the study and accidentally treated with the method of respiratory support as "continuous positive airway pressure " for a maximum of 2-3 days. In this method, a single pronge is used 3-4 centimeters inside the nose. During the treatment, if the baby needs surfactant, based on clinical signs and chest radiography, the method of insure will be operated, and after extubation, the baby will be back to the previous settings. the brand of device used will be "Cindy" or "Ventilator" the amount of oxygen that reaches the patient in each inspiratory is regulated by 40-70% and the positive end expiratory pressure will be 4-6 centimeters of water. Intervention failure in this method is defined as continuous oxygen saturation below 90%, persistence of clinical symptoms or respiratory score above 5. After the disease has healed, other methods such as oxygen therapy with an oxyhood or a mask are used. Intervention 2: Intervention group 2: Infants with a gestational age of 28-34 weeks, weighing less than 2000 grams and hospitalized in the neonatal intensive care unit with a diagnosis of respiratory distress during the first 24 hours of birth, entered the study and accidentally treated with the method of respiratory support as "high frequency oscillation " for a maximum of 2-3 days. In this method, a single pronge is used 3-4 centimeters inside the nose. During the treatment, if the baby needs surfactant, based on clinical signs and chest radiography, the method of insure will be operated, and after extubation, the baby will be back to the previous settings. the brand of device used will be "Stephanie Soufie"; the open airway pressure will be set at 10 centimeters of water and the frequency of the device will be 6-8 hertz. Intervention failure in this method is defined as continuous oxygen saturation below 90%, persistence of clinical symptoms or respiratory score above 5. After the disease has healed, other methods such as oxygen therapy with an oxyhood or a mask are used.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Information on study outcomes can be shared.

When:
6 months after publication of results.

To whom:
Free and academic researchers

Conditions:
Only information about the outcomes of the study is provided, which is unimpeded if the material and intellectual rights of the Maternal and Fetal Research Center are protected.

Where to obtain:
Maternal, fetal &amp; Neonatal Research Center, Valiasr Hospital, Imam Khomeini Hospital Complex, Keshavarz Boulevard, Tehran, Iran

How to obtain:
Visit in research center or communication by email:
mfnhrc@tums.ac.ir

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Raheleh Moradi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Maternal, fetal &amp; Neonatal Research Center, Valiasr Hospital, Imam Khomeini Hospital Complex, Keshavarz Boulevard</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۱۴۱۹۷۳۳۱۴۱</zip>
        <telephone>+98 21 6119 2357</telephone>
        <email>raheleh.moradi1987@gmail.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Tahereh Esmaeilnia</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Maternal, fetal &amp; Neonatal Research Center, Valiasr Hospital, Imam Khomeini Hospital Complex, Keshavarz Boulevard</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۱۴۱۹۷۳۳۱۴۱</zip>
        <telephone>0098 61192357</telephone>
        <email>tesmaeilnia@sina.tums.ac.ir</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>All premature neonates (gestational age of 28-34 weeks)
Neonates with birth weight less than 2000 gr.
Hospitalization in the neonatal intensive care unit due to respiratory distress during the first 24 hours after birth</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>28 days</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Severe asphyxia (apgar of minutes 5 less than or equal to 6)
Positive blood culture upon arrival at the neonatal intensive care unit
Congenital malformations (whether pulmonary or extrapulmonary)</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>P22</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Respiratory distress of newborn</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Treatment - Devices</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1: Infants with a gestational age of 28-34 weeks, weighing less than 2000 grams and hospitalized in the neonatal intensive care unit with a diagnosis of respiratory distress during the first 24 hours of birth, entered the study and accidentally treated with the method of respiratory support as "continuous positive airway pressure " for a maximum of 2-3 days. In this method, a single pronge is used 3-4 centimeters inside the nose. During the treatment, if the baby needs surfactant, based on clinical signs and chest radiography, the method of insure will be operated, and after extubation, the baby will be back to the previous settings. the brand of device used will be "Cindy" or "Ventilator" the amount of oxygen that reaches the patient in each inspiratory is regulated by 40-70% and the positive end expiratory pressure will be 4-6 centimeters of water. Intervention failure in this method is defined as continuous oxygen saturation below 90%, persistence of clinical symptoms or respiratory score above 5. After the disease has healed, other methods such as oxygen therapy with an oxyhood or a mask are used.</i_keyword>
      <i_keyword>Intervention group 2: Infants with a gestational age of 28-34 weeks, weighing less than 2000 grams and hospitalized in the neonatal intensive care unit with a diagnosis of respiratory distress during the first 24 hours of birth, entered the study and accidentally treated with the method of respiratory support as "high frequency oscillation " for a maximum of 2-3 days. In this method, a single pronge is used 3-4 centimeters inside the nose. During the treatment, if the baby needs surfactant, based on clinical signs and chest radiography, the method of insure will be operated, and after extubation, the baby will be back to the previous settings. the brand of device used will be "Stephanie Soufie"; the open airway pressure will be set at 10 centimeters of water and the frequency of the device will be 6-8 hertz. Intervention failure in this method is defined as continuous oxygen saturation below 90%, persistence of clinical symptoms or respiratory score above 5. After the disease has healed, other methods such as oxygen therapy with an oxyhood or a mask are used.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Success or failure of any method. Timepoint: Maximum 3 days. Method of measurement: Need for endotracheal intubation or pulmonary or extrapulmonary complications.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-09-30</approval_date>
        <contact_name>Medical Ethics Committee of Tehran University of Medical Sciences</contact_name>
        <contact_address>Maternal, fetal &amp; Neonatal Research Center, Valiasr Hospital, Imam Khomeini Hospital Complex, Keshavarz Boulevard Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
